SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hirst C, Cook S, Dai W, Perez-Gutthann S, Andrews E. A call for international harmonization in therapeutic risk management. Pharmacoepidemiol Drug Saf 2006; 15: 83949.
  • 2
    Levine A, Fogelman R, Sirota L, Zangen Z, Shamir R, Dinari G. QT interval in children and infants receiving cisapride. Pediatrics 1998; 101: E9.
  • 3
    Drolet B, Khalifa M, Daleau P, Hamelin BA, Turgeon J. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998; 97: 20410.
  • 4
    Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001; 96: 1698703.
    Direct Link:
  • 5
    Walker AM, Szneke P, Weatherby LB, Dicker LW, Lanza LL, Loughlin JE, Yee CL, Dreyer NA. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med 1999; 107: 35662.
  • 6
    Enger C, Cali C, Walker AM. Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. Pharmacoepidemiol Drug Saf 2002; 11: 47786.
  • 7
    Zheng ZJ, Croft JB, Giles WH, Ayala CI, Greenlund KJ, Keenan NL, Neff L, Waltigney WA, Mensah GA. State-specific mortality from sudden cardiac death – United States, 1999. MMWR Morb Mortal Wkly Rep 2002; 51: 12326.
  • 8
    Pratt CM, Hertz RP, Ellis BE, Crowell SP, Louv W, Moyé L. Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. Am J Cardiol 1994; 73: 34652.
  • 9
    Hennessy S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF, Glasser DB, Morrison MF, Strom BL. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ 2002; 325: 1070.
  • 10
    Ellidokuz E, Kaya D. The effect of metoclopramide on QT dynamicity: double-blind, placebo-controlled, cross-over study in healthy male volunteers. Aliment Pharmacol Ther 2003; 18: 1515.
  • 11
    Chou CC, Wu D. Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block. Chang Gung Med J 2001; 24: 8059.
  • 12
    Bentsen G, Stubhaug A. Cardiac arrest after intravenous metoclopramide – a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest. Acta Anaesthesiol Scand 2002; 46: 90810.
  • 13
    Hennessy S, Carson JL, Ray WA, Strom BL. Medicaid databasesed. In: Pharmacoepidemiology, 4th edn, ed. StromBL. Chichester, UK: John Wiley and Sons, Inc., 2005; 28194.
  • 14
    Medicare Payment Advisory Commission. Report to the Congress: New Approaches in Medicare. Washington, DC: Medicare Payment Advisory Commission, 2004.
  • 15
    Hennessy S, Leonard CE, Palumbo CM, Newcomb C, Bilker WB. Quality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS). Med Care 2007; 45: 121620.
  • 16
    Staffa JA, Jones JK, Gable CB, Verspeelt JP, Amery WK. Risk of selected serious cardiac events among new users of antihistamines. Clin Ther 1995; 17: 106277.
  • 17
    Hennessy S, Leonard CE, Bilker WB. Researchers and HIPAA. Epidemiology 2007; 18: 518.
  • 18
    Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58: 11617.
  • 19
    Flanders WD, Louv WC. The exposure odds ratio in nested case–control studies with competing risks. Am J Epidemiol 1986; 124: 68492.
  • 20
    Lubin JH, Gail MH. Biased selection of controls for case–control analyses of cohort studies. Biometrics 1984; 40: 6375.
  • 21
    Miettinen O. Estimability and estimation in case-referent studies. Am J Epidemiol 1976; 103: 22635.
  • 22
    Wessling A, Boëthius G. Measurement of drug use in a defined population. Evaluation of the defined daily dose (DDD) methodology. Eur J Clin Pharmacol 1990; 39: 20710.
  • 23
    Greenland S, Drescher K. Maximum likelihood estimation of the attributable fraction from logistic models. Biometrics 1993; 49: 86572.
  • 24
    Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Monographs on Statistics and Applied Probability, Vol. 57. London: Chapman and Hall, 1993.